
Sign up to save your podcasts
Or


Why is palliative care still so often seen as a last resort and what would it take to change that?
In this episode of TJ Talks, Professors Claudia Gamondi (Head of the Palliative and Supportive Care service at Lausanne University Hospital, and Tumori Journal Section Editor) and Claudia Bausewein (Chair of Palliative Medicine at the Ludwig Maximilian University of Munich) explore the cultural barriers that delay the integration of palliative care into everyday oncology practice, including the persistent belief that “palliative” means giving up hope.
From rethinking the language we use to strengthening training and collaboration, they discuss practical ways to bring oncology and palliative care closer together with patients’ quality of life, needs and priorities at the heart of care.
Listen to the conversation and discover how we can make early palliative care part of everyday oncology practice.
See omnystudio.com/listener for privacy information.
Real breakthroughs happen when the research brings together different skills, knowledge and passion. Discover an inspiring perspective on interdisciplinary approaches to CAR-T cell therapies in this episode of TJ Talks, which guests Professor Yael David, Head of the laboratory and associate member of the Programme in Chemical Biology at Memorial Sloan Kettering, interviewed by Dr Francesca De Santis.
The importance of an interdisciplinary approach lies in the fact that it combines chemistry, biology and epigenetics to overcome the limitations of CAR-T cell therapies, particularly in solid tumours, and the metabolic stress within the tumor microenvironment that can compromise the function of immune cells and make them less effective.
Through the development of engineering, computational and AI tools - Prof. David states - the research aims to protect the genetic material of T cells and reprogram their metabolic response. And its ultimate goal is to create next-generation cell therapies that are more resistant, able to adapt to hostile environments, and clinically effective for cancer patients.
Enjoy the TJ Talks podcast.
See omnystudio.com/listener for privacy information.
The BENCHISTA – International Benchmarking of Childhood Cancer Survival by Tumor stage – project is a worldwide collaboration led by University College London (UCL) and Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT) aiming to better understand the reasons behind international differences in paediatric cancer survival: the project highlights the importance of high-quality data collected through population-based cancer registries as the essential first step in encouraging healthcare systems to invest seriously in improving care for their populations.
In this TJ Talks podcast – by Dr Laura Botta (Evaluative Epidemiology Unit at INT) – Professor Kathy Pritchard-Jones, Emeritus Professor of Paediatric Oncology at UCL and former President of the International Society of Paediatric Oncology (SIOP), explains how the BENCHISTA project is evolving and how the use of its data could contribute to further improvements in survival outcomes for children with cancer.
Enjoy your listening!
See omnystudio.com/listener for privacy information.
What emerges from the most recent first line trials is that the progress in advanced ovarian cancer depends not only on new treatment, but on the better patient selection: not all patients are in the same situation. And the most appropriate treatment must be determined for each individual: the best treatment for each patient.
Within the complex clinical landscape of advanced ovarian cancer, the need for a multidisciplinary approach and ongoing clinical research — in both surgical and medical fields — makes it essential for these patients to be treated in specialist centres, where the necessary expertise and experience are available to decide the best treatment.
Professor Domenica Lorusso, Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X in Milan and a Full Professor of Obstetrics and Gynaecology at Humanitas University in Rozzano (Italy), hosts this TJ Talks, which explores future treatment strategies for the advanced ovarian cancer, with her skilled guests: Dr. Fabio Martinelli, expert in gynecological oncology surgery, and Dr. Elena Giudice, expert in gynecological medical oncology treatment, both from the Gynaecological Oncology Unit at Humanitas Hospital San Pio X.
See omnystudio.com/listener for privacy information.
Caught between enthusiasm for technical innovation and the need for a critical assessment of research practices, the oncology is seeking a new path that offers real hope for effective treatments and a fair distribution of resources for the benefit of patients, because, as Prof. Gyawali’s elderly patient suggests, the real issue is that the quality of life depends entirely on the patient's perspective, which should not be ignored.
Enjoy listening to this episode of TJ Talks: a passionate reflection on the therapeutic approach, the balance between the acceleration of innovation and what has been proven to work, and the urgent need for a common-sense revolution in oncology. Prof. Bishal Gyawali is medical oncology and professor at Queen's University, (Canada) and, together with Dr Dario Trapani (medical oncologist at the IEO, Milan, Italy) - who is hosting the podcast on this occasion - is one of the founders of the Common Sense Oncology Movement, launched in 2023.
See omnystudio.com/listener for privacy information.
Imparare a governare l'innovazione: questo l'invito che il cosiddetto Common Sense Oncology rivolge alla comunità oncologica per un approccio terapeutico interamente centrato sui bisogni del paziente. Alla base del ragionamento c'è una domanda semplice: siamo sicuri che più trattamento significhi sempre migliore medicina?
E per comprendere cosa comporti trasformare questo principio in politica clinica nel contesto italiano, il dr. Dario Trapani ha incontrato per TJ Talks il prof. Massimo Di Maio, Presidente AIOM, e il dr. Francesco Perrone, Presidente della Fondazione AIOM, impegnati da tempo a portare il Common Sense Oncology dal piano del dibattito a quello dell'azione.
See omnystudio.com/listener for privacy information.
From advances in the screening of prostate cancer to the management of the genitourinary tumors, the GU oncology addresses ever more clinical challenges.
What are the most relevant challenges in the management of the prostate cancer population? "It is crucial to balance the right treatment strategy with the right endpoint for patients": Professor Silke Gillessen gets straight to the point of the question posed by Dr Giuseppe Procopio, Head of the Department of Genitourinary Medical Oncology Unit at IRCCS National Cancer Institute Milan, and Editor of the GU Section of the Tumori Journal.
The guest expert of this TJ Talks podcast is Silke Gillessen, Medical and Scientific Director of the Oncology Institute of Southern Switzerland and Full Professor at University of Italian Switzerland, focusing her research in genitourinary areas. In terms of endpoints - she continues - overall survival is the gold endpoint. But when it comes to metastatic prostate cancer, it is necessary to aim for a mix of quality of life, which is very important, and oncological outcomes. These should include improvements related to patients' quality of life, such as time to progression and time to symptomatic events. Patients remind us that we must think not only about the disease, but also about their well-being.
Learn more about the genitourinary cancer care scenario from one of the leading voices in the field.
Enjoy your listening!
See omnystudio.com/listener for privacy information.
The choice of an endpoint can really change the way a treatment is administered or approved for use on patients. And in the future, we will see much more data on quality of life, and trials will probably also work on validating surrogate endpoints and biomarkers.
In this TJ Talks dedicated to the hot topic of endpoints in clinical trials, Gabriele Zoppoli, Associate Professor of Medicine at University of Genoa and Internal Medicine Consultant at Policlinico San Martino (Genoa) meet Erman Akkus, MD at Ankara University, Faculty of Medicine, Department of Medical Oncology.
Alongside “primary clinical endpoints”, which concern overall survival and quality of life, surrogate endpoints are early or indirect measures of these primary endpoints, such as progression-free survival and response rate. Their purpose? To facilitate clinical trials and drug approval, but surrogate endpoints are still an active area of research and are the subject of debate in oncology. Meanwhile, patients' perceptions are waiting to be taken more seriously.
Get insights, listen to the TJ Talks podcast
See omnystudio.com/listener for privacy information.
Pharmaco-prevention of breast cancer is an evidence-based strategy that uses drugs to reduce the risk of disease in high-risk women. However, the use of this strategy remains modest due to concerns about toxicity, low awareness and difficulties in patient selection.
In this TJ Talks podcast, together with Prof. Andrea De Censi, director of the Breast Unit at the Champalimaud Foundation in Lisbon, Portugal, here in conversation with Prof. Antonino Musolino (director of the Medical Oncology Unit at the IRCCS-Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Forlì-Cesena), we will examine what practical solutions can bridge the gap between pharmacological prevention, indication and adoption, with a look at the future perspectives in this setting.
Enjoy your listening!
See omnystudio.com/listener for privacy information.
Stories of foreign cancer patients who ask to return to their country at the end of their lives: their deep desire to see their loved ones one last time is intertwined with medical, legal and financial issues that seem insurmountable. In this TJ Talks, Dr Sergio Defendi, director of Palliative Care and Home Care at Asst Crema, who has been providing assistance with end-of-life travel for years, discusses this issue together with Dr Luca Zambelli, from the Palliative Care Unit of the IRCCS National Cancer Institute Foundation in Milan.
How should the responsibility for end-of-life repatriation be managed? Clinical uncertainty, the legal issue of the use of certain drugs, and the protection of patients and accompanying doctors should be addressed in guidelines or care pathways that deal with this sensitive issue. This is the next challenge for the oncology community.
Enjoy your listening!
See omnystudio.com/listener for privacy information.
From the publisher's feed
TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal.
The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care.
Follow us on X, Bluesky and LinkedIn to always be updated on cancer research and clinical practice in oncology!